Today it was reported that the CEO of Spark Therapeutics (ONCE), Jeffrey Marrazzo, exercised options to buy 6,000 ONCE shares at $3.45 a share, for a total transaction value of $20.7K.
This recent transaction increases Jeffrey Marrazzo’s holding in the company by 2.05% to a total of $11.72 million.
See today’s analyst top recommended stocks >>
Based on Spark Therapeutics’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $10.71 million and GAAP net loss of $47.36 million. In comparison, last year the company earned revenue of $7.41 million and had a GAAP net loss of $61.82 million. Currently, Spark Therapeutics has an average volume of 446.2K.
Based on 13 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $62.18, reflecting a 59.0% upside. Eight different firms, including B.Riley FBR and Cantor Fitzgerald, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases.
